AI / ML Innovations Tech2Heal Prepares Remote Patient Monitoring Platform for Deployment
News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.
Product deployment and pilot studies planned for the fourth quarter of 2021
TORONTO, ON / ACCESSWIRE / September 28, 2021 / AI / ML Innovations Inc. (CSE: AIML) (OTCQB: AIMLF) (FSE: 42FB), a company committed to acquiring and advancing artificial intelligence / machine learning technologies that meet urgent societal needs, is pleased to announce that its minority-owned company subsidiary Tech2Heal SAS is preparing its Alakin RPM (remote patient monitoring) platform for deployment during the fourth quarter of this year.
The MVP (Minimum Viable Platform) version of Alakin is expected to launch in the fourth quarter of this year, alongside initial pilot studies being rolled out with several major healthcare providers located in Europe and South America.
Tech2Heal pioneered ‘Alakin’, a scalable SaaS (‘software as a service’) digital therapy and remote patient monitoring platform that enables hospitals and clinics to effortlessly undertake value-based care programs “Without code” with their patients. At its core, Alakin is a tailor-made comprehensive platform with a rich feature set that includes the ‘clinical builder’ (a core product feature that allows for almost unlimited configurability of patient clinical protocols), Integrated telemedicine, a triage dashboard, calendars, fully scalable integrated patient records and more, which combine into a versatile and powerful tool that can save valuable healthcare provider resources while simultaneously helping to improve outcomes for patients.
Alakin offers a B2B subscription model, with a monthly subscription per patient integrated into each healthcare provider’s system. The main target users are medical clinics, hospitals, ACOs and individual medical practices. Integral to its successful deployment, Alakin offers a method to accelerate innovative services to healthcare teams and patients, in line with new regulations regarding value-based payments found in markets such as the United States, Europe. and Brazil. An advantage of Alakin for its targeted users is that clinicians can launch their own basket of remote patient monitoring services and / or digital therapy within hours, without having to use any computer code. In addition, plans are underway to move Alakin to a “results-based” pricing structure in some markets, as is the case with some US healthcare providers.
About Tech2Heal (DBA Tech2Health)
Tech2Heal is a digital health innovator based in Paris, France with a portfolio of wellness and health technology products and services designed to improve an individual’s mental well-being using a unique blend of ‘exclusive digital assets, remote live advice and a physical wellness center. . Tech2Health has developed a clinically supported, evidence-based methodology consisting of psychotherapies and non-medicinal interventions that apply healing techniques to the body and mind, delivered through a secure digital platform.
Tech2Health’s first product, Qookka Live, provides mental and emotional health prevention and support services to businesses and health insurers from a single, cohesive application. Qookka Live offers simple and intuitive access to licensed therapists and their patients, and complements these consultations with digital courses and live wellness coaching sessions in six areas: meditation, mindfulness, yoga, art therapy, Tai chi and Qi Qong.
About IA / ML Innovations Inc.
AI / ML Innovations Inc. has realigned its business operations to capitalize on the growing areas of Artificial Intelligence (AI) and Machine Learning (ML), with an initial investment focused on emerging healthcare and healthcare companies. digital wellness that leverage AI, ML, and cloud computing. and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (22% owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding areas of growth, for the benefit of all stakeholders in the company. AI / ML shares trade on the Canadian Stock Exchange under the symbol “AIML”, on the OTCQB Venture Market under “AIMLF” and on the Frankfurt Stock Exchange under “42FB”.
On behalf of the board of directors
Tim Daniels, Executive Chairman
For more information on AI / ML innovations:
For detailed information, please see AI / ML’s website at https://aiml-innovations.com/ or company filings at www.sedar.com.
For more information: Blake Fallis at (778) 405-0882 or [email protected]
Corporate video: https://www.youtube.com/watch?v=k2QSjo7clXc&feature=youtu.be
Official YouTube channel: https://www.youtube.com/channel/UCCfOj2P_Fu3TOK6Jl1G9vEQ
Neither CSE nor its regulatory services provider (as that term is defined in CSE policies) accepts responsibility for the adequacy or accuracy of this release.
Cautions and forward-looking statements
Certain information contained in this press release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the control of the Company, including, but not limited to, the uncertainty of competition from other industry players, the ‘impact of general economic conditions, industry conditions, dependency subject to regulatory approvals and the ability to raise additional capital as needed in the future. Readers are cautioned that the assumptions used in preparing this information, while believed to be reasonable at the time of preparation, may prove to be imprecise and that forward-looking statements should not be relied on unduly. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
The forward-looking statements contained in this press release are made as of the date of this press release, and the Company assumes no obligation to publicly update or revise any forward-looking statements included, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.
THE SOURCE: AI / ML Innovations Inc.
See the source version on accesswire.com: